GLTO (Galecto) Forward PE Ratio : 0.00 (As of Apr. 12, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Galecto Forward PE Ratio?

Galecto's Forward PE Ratio for today is 0.00.

Galecto's PE Ratio without NRI for today is 0.00.

Galecto's PE Ratio (TTM) for today is 0.00.

Galecto Forward PE Ratio Historical Data

The historical data trend for Galecto's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galecto Forward PE Ratio Chart

Galecto Annual Data

Trend

Forward PE Ratio

Galecto Quarterly Data

Forward PE Ratio

Competitive Comparison of Galecto's Forward PE Ratio

For the Biotechnology subindustry, Galecto's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galecto's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galecto's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Galecto's Forward PE Ratio falls into.

Save Embed

;

Save Embed

;

Galecto Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Galecto (NAS:GLTO) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Galecto Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Galecto's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Galecto Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galecto Inc (NAS:GLTO) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.galecto.com

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Executives

Hans T. Schambye	director, officer: Chief Executive Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Garrett Winslow	officer: General Counsel	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bertil Lindmark	officer: Chief Medical Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Stephanie Oestreich	officer: Chief Business Officer	75 STATE STREET, SUITE 100, BOSTON MA 02109
Jonathan Freve	officer: Chief Financial Officer	C/O SPRING BANK PHARMACEUTICALS, INC., 113 CEDAR STREET, STE S-7, MILFORD MA 01757
Anne Prener	director	C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
Dallas Jayson Donald Alexander	director	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Chau Quang Khuong	director, 10 percent owner	C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Stephan Christgau	director	C/O CASTLE & MORGAN HOLDINGS, INC., 425 MARKET STREET, SUITE 2230, SAN FRANCISCO CA 94105
Soren Moller	director	C/O NOVO HOLDINGS A/S, TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Anders Pedersen	officer: Chief Operating Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Orbimed Advisors Israel Ii Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Israel Gp Ii, L.p.	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022